Rilvegostomig
- Generic Name
- Rilvegostomig
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Phase 3
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT06109779
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2
Recruiting
- Conditions
- Hepatocellular CarcinomaBiliary Tract Cancer
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT05775159
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2
Recruiting
- Conditions
- Endometrial CancerGastric CancerMetastatic Castration-resistant Prostate CancerOvarian CancerColorectal CancerUrothelial CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Phase 2
Recruiting
- Conditions
- Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 200
- Registration Number
- NCT05414032
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Canada
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed/CisplatinDrug: Pemetrexed/CarboplatinDrug: Carboplatin/Paclitaxel
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 199
- Registration Number
- NCT04995523
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT04686305
- Locations
- 🇹🇷
Research Site, Bornova-Izmir, Turkey
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 371
- Registration Number
- NCT04612751
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath